BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li HL, Wu X, Xu A, Hoo RL. A-FABP in Metabolic Diseases and the Therapeutic Implications: An Update. Int J Mol Sci 2021;22:9386. [PMID: 34502295 DOI: 10.3390/ijms22179386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Francisco V, Sanz MJ, Real JT, Marques P, Capuozzo M, Ait Eldjoudi D, Gualillo O. Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets? Biology 2022;11:1237. [DOI: 10.3390/biology11081237] [Reference Citation Analysis]
2 Gu M, Lin Y, Gai X, Wei X, Lu C, Wang Y, Ding X, Peng Y, Ma Y. High Serum FABP4 Levels are Negatively Associated with the Reversion from Prediabetes to Normal Glucose Tolerance: A 2-Year Retrospective Cohort Community Study. DMSO 2022;Volume 15:2217-25. [DOI: 10.2147/dmso.s374912] [Reference Citation Analysis]